Pseudomonas aeruginosa in the ICU: prevalence, resistance profile, and antimicrobial consumption

Rev. Soc. Bras. Med. Trop; 53 (), 2020
Publication year: 2020

Abstract INTRODUCTION:

Pseudomonas aeruginosa is one of the main pathogens causing infection in intensive care units (ICUs) and usually presents antimicrobial resistance.

METHODS:

Data were obtained from ICUs between 2010 and 2013.

RESULTS:

P. aeruginosa had a prevalence of 14.5% of which 48.7% were multidrug resistant. We observed increasing resistance to carbapenems and polymyxin B and growing consumption of aminoglycosides, meropenem, ceftazidime, and polymyxin B. The regression impact between resistance and consumption was significant with respect to amikacin, imipenem, meropenem, and polymyxin B.

CONCLUSIONS:

Monitoring antimicrobial consumption and resistant microorganisms should be reinforced to combat antimicrobial- and multi-drug resistance.

More related